Posts by Christopher

Original Post in The Bay Area Reporter By: Matthew S. Bajko A new endowment named in honor of the pioneering HIV physician Dr. Marcus Conant aims to help educate future generations of health care providers interested in caring for people living with HIV and LGBTQ individuals. It has a particular focus on those entering the…

Addimmune™ CEO Jeff Galvin joins ShareTreck host Raj Natarajan in this compelling interview to discuss the company’s launch as well as updates on AGT103-T, Addimmune’s HIV therapeutic. Following a successful Phase 1 clinical trial, will build AGT’s success, accelerating the clinical development with dedicated investment and singular focus on HIV. 

CEO Jeff Galvin joins NBC 4 to discuss the success of AGT’s Phase 1 HIV gene and cell therapy clinical trial, as well as plans to advance to Phase 2 through Addimmune™ – a new spinoff company harnessing gene and cell therapy technologies for a potential HIV cure. Addimmune will focus solely on HIV research…

Original Post in DC News Now. By: Shennekia Grimshaw American Gene Technologies (AGT™), a clinical-stage biotechnology company based in Rockville, Maryland, is launching a new company – Addimmune – to continue to develop gene and cell therapy technologies to cure HIV. Addimmune will focus solely on advancing an HIV cure, building upon more than a…

Original Post in WTOP By: Jeff Clabaugh There are treatments to keep HIV patients healthy and the virus at bay, but there is still no known cure. A Rockville, Maryland, company thinks it’s headed in the right direction. American Gene Technologies, a 15-year-old gene therapy biotech company with no products on the market, cites strong,…

Original Post in WBJ By: Sara Gilgore Rockville’s American Gene Technologies is spinning off a new company that will look to raise millions of dollars in funding and potentially go public – with an ambitious goal of curing HIV.  The private, 16-year-old biotech, which does not yet have a product to market, said Friday it…

Original Post in BioBuzz By: Alex Keown Powered by promising Phase I results from its HIV gene and cell therapy, American Gene Technologies (AGT) is spinning off a new company dedicated solely to develop a cure for a disease Chief Executive Officer Jeff Galvin calls ‘insidious.” The new company, called Addimmune, will build on the…

Original Post in BioWorld By: Lee Landenberger For Jeff Galvin, the CEO and founder of newly launched Addimmune, HIV is not a condition that’s in the rearview mirror. It needs a functional cure to save lives, make people healthier and save money that need not have been spent.  People wonder why it’s worth bothering to…

Original Post in MoCo 360 A Rockville gene therapy company is determined to find a cure for HIV – and recent studies suggest it might be on the right track. American Gene Technologies, a 15-year-old company founded and run by CEO Jeff Galvin, conducted several clinical trials with “strong, positive results” indicating a potential cure…